Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: A beta regression meta-analysis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 5, 2012, Pages 479-498

  Rogers, James A ^a   Polhamus, Daniel ^a   Gillespie, William R ^a   Ito, Kaori ^b   Romero, Klaus ^c   Qiu, Ruolun ^b   Stephenson, Diane ^c   Gastonguay, Marc R ^a   Corrigan, Brian ^b  

^a Metrum Research Group   (United States)

^b PFIZER INC   (United States)

^c CRITICAL PATH INSTITUTE   (United States)

Author keywords

ADNI; Alzheimer's disease; Bayesian; Beta regression; CAMD; Disease progression; Logistic; Longitudinal; Meta analysis

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; EXTERNAL VALIDITY; HUMAN; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; META ANALYSIS (TOPIC); NEUROIMAGING; PLACEBO EFFECT; PREDICTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROBABILITY; PROCESS DEVELOPMENT; PROCESS MODEL; RATING SCALE; REGRESSION ANALYSIS; SCORING SYSTEM;

ALZHEIMER DISEASE; DATABASES, FACTUAL; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; STATISTICS AS TOPIC;

EID: 84870466420     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9263-3     Document Type: Article

References (26)

1. Agresti A (1990) Categorical data analysis. Wiley, New York
2. Ashford JW, Schmitt FA (2001) Modeling the time-course of alzheimer dementia. Curr Psychiatry Rep 3(1):20-28
3. Ferrari S, Cribari-Neto F (2004) Beta regression for modelling rates and proportions. J Appl Stat 31(7):799-815
4. Gastonguay MR, French JL, Heitjan DF, Rogers JA, Ahn JE, Ravva P (2010) Missing data in model-based pharmacometric applications: points to consider. J Clin Pharmacol 50 (Suppl 1):63S
5. Gelman A, Carlin JB, Stern HS, Rubin DB (2004) Bayesian data analysis. Chapman & Hall/CRC, New York
6. Gelman A, Van MI, Verbeke G, Heitjan DF, Meulders M (2005) Multiple imputation for model checking: completed-data plots with missing and latent data. Biometrics 61(1):74-85
7. Gillespie WR, Rogers JA, Ito K, Gastonguay MR (2009) Population dose-response model for adas-cog scores in patients with alzheimers disease by meta-analysis of a mixture of summary and individual data. In: American Conference on Pharmacometrics. Mashantucket
8. Holford NH, Peace KE (1992) Methodologic aspects of a population pharmacodynamic model for cognitive effects in alzheimer patients treated with tacrine. Proc Natl Acad Sci 89(23): 11,466 -11,470 http://www.pnas.org/content/ 89/23/11466.abstract
9. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T (2010) Alzheimer's disease working group: disease progression meta-analysis model in alzheimer's disease. Alzheimers Dement 6(1):39-53. doi:10.1016/j.jalz.2009.05. 665
10. Ito K, Corrigan B, Zhao Q, French J, Miller R, Soares H, Katz E, Nicholas T, Billing B, Anziano R, Fullerton T (2011) Alzheimer's disease neuroimaging initiative: disease progression model for cognitive deterioration from alzheimer's disease neuroimaging initiative database. Alzheimers Dement 7(2):151-160. doi: 10.1016/j.jalz.2010.03.018
11. Kieschnick R, McCullough BD (2003) Regression analysis of variates observed on (0, 1): percentages, proportions and fractions. Stat Model 3:192-213
12. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR (2005) How vague is vague? a simulation study of the impact of the use of vague prior distributions in mcmc using winbugs. Stat Med 24(15):2401-2428. doi:10.1002/sim.2112
13. L'Ecuyer P, Simard R, Chen EJ, Kelton WD (2001) An objectoriented random-number package with many long streams and substreams. Oper Res 50:1073-1075
14. Little RJA, Rubin DB (2002) Statistical analysis with missing data, 2nd edn. Wiley, New York
15. Ludden TM, Beal SL, Sheiner LB (1994) Comparison of the akaike information criterion, the schwarz criterion and the f test as guides to model selection. J Pharmacokinet Biopharm 22(5):431-445
16. Lunn D, Thomas A, Best N, Spiegelhalter D (2000) Winbugs - a bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 10:325-337
17. Mohs RC, Rosen WG, Davis KL (1983) The alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 19(3):448-450
18. Olkin I, Tate RF (1961) Multivariate correlation models with mixed discrete and continuous variables. Ann Math Stat 32(2): 448-465
19. R Development Core Team (2008) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. http://www.R-project.org. ISBN: 3-900051- 07-0
20. Romero K, Corrigan B, Neville J, Kopko S, Cantillon M (2011) Striving for an integrated drug-development process for neurodegeneration: the coalition against major diseases. Neurodegener Dis Manag 1(5):379-385
21. Romero K, de Mars M, Frank D, Anthony M, Neville J, Kirby L, Smith K, Woosley RL (2009) The coalition against major diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin Pharmacol Ther 86(4):365-367. doi:10.1038/clpt.2009.165
22. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for alzheimer's disease. Am J Psychiatry 141(11):1356-1364
23. Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, DiBernardo A, Narayan V (2012) Alzheimer's disease neuroimaging initiative: an improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol 52(5): 629-644
24. Stukel TA (1988) Generalized logistic models. J Am Stat Assoc 83(42):426-431
25. Tsoularis A, Wallace J (2002) Analysis of logistic growth models. Math Biosci 179(1):21-55
26. Williams-Faltaos D, Ying C, Wang Y, Gobburu J, Zhu H, Quantification of disease progression and drop-out for Alzheimer's disease. Technical report, Food and Drug Administration